Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
51285-0367-01 51285-0367 Methotrexate Trexall 7.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0368-01 51285-0368 Methotrexate Trexall 10.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51285-0369-01 51285-0369 Methotrexate Trexall 15.0 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 3, 2001 In Use
51672-4118-02 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-05 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
51672-4118-06 51672-4118 Fluorouracil Fluorouracil 50.0 mg/g Chemotherapy Antimetabolite Pyrimidine Analog Topical March 17, 2017 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec. 11, 2015 In Use
50242-0130-86 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Oct. 10, 2017 In Use
54569-1818-09 54569-1818 METHOTREXATE, Methotrexate sodium Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Dec. 7, 1953 In Use
54868-5474-00 54868-5474 Erlotinib Hydrochloride Tarceva 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 21, 2005 In Use
55111-0556-10 55111-0556 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 11, 2013 In Use
57962-0070-28 57962-0070 Ibrutinib IMBRUVICA 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Dec. 20, 2017 In Use
57962-0140-09 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0140-12 57962-0140 Ibrutinib Imbruvica 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Nov. 13, 2013 In Use
57962-0280-28 57962-0280 Ibrutinib IMBRUVICA 280.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-28 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 In Use
57962-0420-71 57962-0420 Ibrutinib IMBRUVICA 420.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 6, 2019 In Use
60687-0149-94 60687-0149 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2016 In Use
61703-0309-06 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-16 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Jan. 1, 1996 In Use
61703-0309-25 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Nov. 27, 2013 In Use
61703-0309-26 61703-0309 Vincristine Sulfate Vincristine Sulfate 1.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 19, 2014 In Use
61703-0323-22 61703-0323 Bleomycin Bleomycin 30.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 10, 2000 In Use
61703-0332-18 61703-0332 Bleomycin Bleomycin 15.0 [USP'U]/1 Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intramuscular, Intrapleural, Intravenous, Subcutaneous April 11, 2000 In Use
61703-0339-18 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-22 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-50 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 14, 2004 In Use
61703-0339-56 61703-0339 Carboplatin Carboplatin 10.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Nov. 23, 2004 In Use
61703-0343-18 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-65 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0343-66 61703-0343 Mitoxantrone Mitoxantrone 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracenedione Intravenous April 11, 2006 In Use
61703-0349-09 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-16 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0349-36 61703-0349 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 27, 2008 In Use
61703-0363-18 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
61703-0363-22 61703-0363 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug. 10, 2009 In Use
62484-0020-01 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62484-0020-02 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62856-0177-08 62856-0177 Carmustine implant/ polifeprosan 20, polifeprosan 20 with carmustine implant Gliadel 7.7 mg/1 Chemotherapy Alkylating Agent Nitrosourea Intracavitary In Use
63323-0117-10 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 2, 2017 In Use
63323-0117-18 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-19 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-20 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 2, 2017 In Use
63323-0117-28 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-51 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-58 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-59 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-61 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-68 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use
63323-0117-69 63323-0117 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 12, 2000 In Use

Found 10,000 results in 5 milliseconds — Export these results